Walk-In Interview for QA, Q.C. Manufacturing, Eng.Jobs in USV Pvt Ltd on 8th may
In India we are recognized for our leadership in the Oral Anti-Diabetic market where we rank No. 1 by Rx and Value. In the Cardiovascular diseases segment we are No. 1 by Rx and in the top 8 by Value. We also have a significant presence in the areas of Vitamins, Minerals, Nutrients, Dermatology, Gastroenterology and CNS.
We are 2000 carore health care company with operations in India, US & EU, with leadership in diabetes and cardiovascular segments. We provide a supportive and learning, environment where personal growth is encouraged and nurtured. We have three plants based at Daman and Baddi manufacturing Tablets, Capsules: Sterile injectables & Ophthalmic Products, one API plant at Chiplun and biotechnology facility in Nerul Mumbai. All our plants are approved by US, EU, Health Canada and other leading country's regulators
here is I am giving information about Interview on 8th may
We have scheduled Walk-In for USV Pvt Ltd., Daman Plant on 8th May, 2016 (Sunday)
USV Pvt Ltd.-Daman Plant
Date: 8th May, 2016 - SUNDAY
TIME: 10:00 AM to 04:00 PM
Job Location: Daman
Vacancy for Different Areas are:
- Quality Control
- Quality Assurance
Candidates may Walk-In for an interview along with their updated Resume,updated salary slip
USV Pvt Ltd.
Office no: 02606636229/232
Great Place To Work
Value addition at all levels of the organisation chain is essential and necessary for the growth and success of our company. To ensure this, USV provides an environment that:
- Values people
- Promotes learning
- Nurtures innovation
- Rewards collective excellence
We are a 53 year old leading healthcare company which began as a joint venture with USV&P Inc. USA, a subsidiary of Revlon. Our product offering today includes Active Pharmaceutical Ingredients (APIs), Fixed Dosages Formulations (FDF), Peptides, Biosimilars and Injectables. These are manufactured in our cGMP compliant plants located in India.
We market our products globally to 75 countries. In the financial year 2013-14, our total income was Rs. 20,099 million. Our Indian business contributed 78% to the revenue and the rest was from export of APIs and Finished Dosages.
Our international business consists of:
- A large portfolio of small molecule APIs. Of the 52 products in our portfolio, 27 APIs are commercially available, while others are in various stages of development. Our special skills include production and characterization of polymorphs and particle sizing
- A portfolio of Finished Dosages. These include immediate release, modified release and products with 'complex' characteristics which are promoted through ANDA filings and Dossiers linked to supply.
Our spend of 7.35% of sales on R&D ensures that we are able to deliver on our research portfolio. We have over 100,000 sq. ft. of laboratory space with excellent infrastructure. Our research is driven by a team of 262 scientists including 2 doctors, 31 PhDs and 229 post-graduates, many of whom have studied in universities in USA, Europe and Japan. Our intellectual property portfolio consists of patent filings for 43 inventions of which 18 have been granted.